An Intelligence-Driven Approach To Partnering
An Interview With A Rising Leader, C4X Discovery's Bhavna Hunjan
Her experience in banking and consultancy helped C4XD strategy chief Bhavna Hunjan to build a team that drives corporate development through partnerships, with a focus on attractive preclinical data packages to out-license to pharmaceutical companies.
You may also be interested in...
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.